Deputy Chief Medical Officer Dr John Burke explains our process for authorising treatments.
In this archive we aim to publish our commissioned reviews into the clinical evidence available for selected treatments, alongside our decision on whether we will authorise these treatments.
Review #1: use of ImmunoCAP ISAC and ImmunoCAP Components for allergy testing, June 2020. Conclusion: red/not authorised.
Download ImmunoCAP review hereReview #2: is there any new evidence to support the use of eXroid for the treatment of haemorrhoids? Conclusion: red/not authorised.
Download eXroid review hereReview #3: are high-intensity focused ultrasound (HIFU), irreversible electroporation (IRE) and cryotherapy recommended treatments in prostate cancer? Conclusion: amber/not authorised.
Download prostate cancer treatments review hereReview #4: is LINX for reflux safe and effective and for what indications? Conclusion: amber/not authorised.
Download LINX review hereReview #5: what is the evidence for MR-guided radiotherapy? Conclusion: amber/not authorised.
Download MR-guided RT review hereReview #6: what is the evidence for Cartiva implants for great toe metatarsophalangeal joint pain (MTPJ)? Conclusion: red/not authorised.
Download Cartiva implants review hereReview #7: what is the evidence for hyperthermic intraoperative peritoneal chemotherapy (HIPEC) in the prevention of peritoneal carcinomatosis in patients with colorectal cancer? Conclusion: amber/not authorised.
Download HIPEC review here